KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Operating Leases for 4 consecutive years, with $50.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 44.13% year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Sep 2025, down 44.13%, and an annual FY2024 reading of $67.2 million, up 54.9% over the prior year.
  • Operating Leases was $50.0 million for Q3 2025 at Recursion Pharmaceuticals, down from $53.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $89.5 million in Q3 2024 and bottomed at $43.4 million in Q4 2023.
  • Average Operating Leases over 4 years is $52.2 million, with a median of $47.5 million recorded in 2022.
  • The sharpest move saw Operating Leases skyrocketed 102.11% in 2024, then tumbled 44.13% in 2025.
  • Year by year, Operating Leases stood at $44.4 million in 2022, then decreased by 2.26% to $43.4 million in 2023, then surged by 54.9% to $67.2 million in 2024, then dropped by 25.61% to $50.0 million in 2025.
  • Business Quant data shows Operating Leases for RXRX at $50.0 million in Q3 2025, $53.4 million in Q2 2025, and $56.0 million in Q1 2025.